Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
IPO Year: 2021
Exchange: NASDAQ
Website: reneopharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2023 | Outperform → Market Perform | Leerink Partners | |
| 12/15/2023 | Buy → Hold | Jefferies | |
| 12/15/2023 | $30.00 → $1.50 | Buy → Neutral | H.C. Wainwright |
| 12/14/2023 | Buy → Neutral | Ladenburg Thalmann | |
| 12/14/2023 | $23.00 → $1.45 | Buy → Underperform | BofA Securities |
| 12/14/2023 | Outperform → Mkt Perform | William Blair | |
| 12/14/2023 | $28.00 → $3.00 | Outperform → Neutral | Robert W. Baird |
| 12/14/2023 | $25.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 11/15/2023 | $35.54 | Outperform | William Blair |
| 8/28/2023 | $30.00 | Buy | H.C. Wainwright |
4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)
4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)
4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)
4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)
4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)
8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
425 - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
8-K - Reneo Pharmaceuticals, Inc. (0001637715) (Filer)
425 - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
8-K - Reneo Pharmaceuticals, Inc. (0001637715) (Filer)
8-K - Reneo Pharmaceuticals, Inc. (0001637715) (Filer)
EFFECT - Reneo Pharmaceuticals, Inc. (0001637715) (Filer)
424B3 - Reneo Pharmaceuticals, Inc. (0001637715) (Filer)
S-4/A - Reneo Pharmaceuticals, Inc. (0001637715) (Filer)
S-4/A - Reneo Pharmaceuticals, Inc. (0001637715) (Filer)
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Roshawn Blunt to the company's Board of Directors. "Roshawn is an accomplished leader within the biopharma industry," said Mike Grey, Executive Chairman of Reneo Pharmaceuticals. "Her extensive experience in healthcare reimbursement, policy, and patient access will be an invaluable addition to Reneo as we plan for commercialization of REN001 in the U.S. and Europe. We look forward to working with Roshawn o
IRVINE, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced changes to its Board of Directors. Paul W. Hoelscher, Executive Vice President, Chief Financial Officer of Horizon Therapeutics plc, has been appointed to the Board and will serve as chair of the Audit Committee. In conjunction with the appointment of Mr. Hoelscher, Kenneth Harrison, Partner at Novo Ventures (US) Inc., resigned from the Reneo Board of Directors. Reneo also today announced that Lon Cardon, Ph.D. will not seek
IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Ashley F. Hall, JD, to the position of Chief Development Officer. In this role, Ms. Hall will oversee nonclinical and clinical operations, global regulatory affairs, pharmaceutical development, and program management for all the company's development programs. "We are happy to welcome Ashley to the Reneo leadership team," said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals. "Ashley is an expe
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares rose 88.9% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $9.2 million. Dermata Therapeutics (NASDAQ:DRMA) stock rose 12.8% to $3.7. The company's market cap stands at $1.6 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) stock moved upwards by 7.88% to $0.47. The company's market cap stands at $7.8 million. Ocular Therapeutix (NASDAQ:OCUL) shares rose 7.25% to $6.36. The market value of their outstanding shares is at $985.0 million. Unicycive Therapeutics (NASDAQ:UNCY) shares rose 6.02% to $0.89. The company's market cap stands at $33.4 million. Virios Therapeutics (NASDAQ:VIRI) shares
Gainers Akanda (NASDAQ:AKAN) shares rose 177.7% to $0.37 during Friday's pre-market session. The company's market cap stands at $11.7 million. Scorpius Holdings (AMEX:SCPX) stock increased by 28.17% to $0.13. The market value of their outstanding shares is at $4.6 million. NovaBay Pharmaceuticals (AMEX:NBY) shares moved upwards by 27.0% to $0.15. The market value of their outstanding shares is at $5.7 million. ZimVie (NASDAQ:ZIMV) shares moved upwards by 23.61% to $20.99. The company's market cap stands at $572.7 million. Kintara Therapeutics (NASDAQ:KTRA) stock moved upwards by 17.16% to $0.17. The market value of their outstanding shares is at $6.6 million. As per the press release, Q
The Dow Jones index closed lower by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Retractable Technologies The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw bought a total of 1,210 shares at an average price of $1.12. To acquire these shares, it cost around $1,355. What's Happening: On May 15,
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Reneo Pharmaceuticals (NASDAQ:RPHM) with a Neutral and maintains $1.5 price target.
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) shares initially traded higher Monday before turning negative after the company announced a proposed merger with OnKure, Inc. The Details: Reneo and Onkure announced Monday that they have entered into a definitive merger agreement to combine the two companies in an all-stock transaction. The resulting company, expected to operate as OnKure Therapeutics, will focus on advancing OnKure’s products targeting oncogenic mutations in phosphoinositide 3-kinase alpha. This includes OnKure’s lead program OKI-219. “OnKure has an experienced team of drug developers, and we are excited about the potential for OKI-219 to become a meaningful treatment opti
Reneo Pharmaceuticals (NASDAQ:RPHM) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:35 AM. Here's what investors need to know about the announcement. Earnings Reneo Pharmaceuticals missed estimated earnings by -13.0%, reporting an EPS of $-0.7 versus an estimate of $-0.62. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.0 which was followed by a 1.0% increase in the share price the next day. ** Listen to the earnings announcement yourself by clicking here. ** To track all earnings releases for Reneo Pharmaceuticals visit their earnings calendar here. This article was generated by Benzinga's automa
Reneo Pharmaceuticals (NASDAQ:RPHM) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.62) by 12.9 percent. This is a 25 percent decrease over losses of $(0.56) per share from the same period last year.
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
Leerink Partners downgraded Reneo Pharmaceuticals from Outperform to Market Perform
Jefferies downgraded Reneo Pharmaceuticals from Buy to Hold
H.C. Wainwright downgraded Reneo Pharmaceuticals from Buy to Neutral and set a new price target of $1.50 from $30.00 previously
Ladenburg Thalmann downgraded Reneo Pharmaceuticals from Buy to Neutral
BofA Securities downgraded Reneo Pharmaceuticals from Buy to Underperform and set a new price target of $1.45 from $23.00 previously
William Blair downgraded Reneo Pharmaceuticals from Outperform to Mkt Perform
Robert W. Baird downgraded Reneo Pharmaceuticals from Outperform to Neutral and set a new price target of $3.00 from $28.00 previously
Piper Sandler downgraded Reneo Pharmaceuticals from Overweight to Neutral and set a new price target of $4.00 from $25.00 previously
William Blair initiated coverage of Reneo Pharmaceuticals with a rating of Outperform and set a new price target of $35.55
H.C. Wainwright initiated coverage of Reneo Pharmaceuticals with a rating of Buy and set a new price target of $30.00
SC 13D/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
SC 13G/A - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
SC 13D/A - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
SC 13G - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
SC 13D - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
SC 13D/A - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
SC 13D/A - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
SC 13D/A - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
SC 13D/A - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer -- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024 -- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026 -- Shares to trade on Nasdaq under the new ticker symbol "OKUR" commencing on October 7, 2024 BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR) ("OnKure"), a clinical-stage biopharmaceutical company focused on the develo
– Combined company to trade on Nasdaq under ticker "OKUR" – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) ("Reneo") today announced the results of the special meeting of its stockholders held on September 26, 2024. At the special meeting, Reneo's stockholders voted in favor of all proposals, including the proposals required to complete the proposed merger of Reneo and OnKure, Inc. ("OnKure"). The closing of the merger is anticipated to take place on or around Friday, October 4, 2024. Following the closing of the merger, the combined company plans to change its name from "Reneo Pharmaceut
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30, 2024. Second Quarter and Recent Highlights On May 10, 2024, Reneo and OnKure, Inc. entered into a definitive merger agreement to combine the companies in an all-stock transaction (the "Merger").The Merger is expected to create a Nasdaq-listed, clinical stage biopharmaceutical company focused on advancing OnKure's portfolio of precision oncology therapies.The Merger a
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure's portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide funding through multiple clinical milestones and runway into fourth quarter of 2026 IRVINE, Calif., and BOULDER, Colo., May 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that they have entered into a definitive merger agreement to
IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights In December 2023, the pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies did not meet its primary efficacy or secondary efficacy endpointsThe Company implemented cost savings initiatives, including suspension of all mavodelpar development activities and a total workforce reduction of
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. Fourth Quarter and Recent Highlights The pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies (PMM) did not meet its primary efficacy or secondary efficacy endpointsThe Company implemented cost savings initiatives, including suspension of all mavodelpar development activities and a t
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced its pivotal STRIDE study (NCT04535609) of mavodelpar in adult patients with primary mitochondrial myopathies (PMM) did not meet its primary efficacy or secondary efficacy endpoint. The primary efficacy endpoint of the trial was the change from baseline in the distance walked during the 12-
IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. "We are looking forward to sharing topline results of our pivotal STRIDE study in December," said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals. "In addition, we continue to be encouraged by the high participation rate in our STRIDE AHEAD open-label extension study, and are happy to announce enrollment of our first p
IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company's management team will participate in the following investor conferences. Jefferies London Healthcare Conference Date: Tuesday, November 14 – Thursday, November 16, 2023 Location: The Waldorf Hilton, London, UK Piper Sandler & Co. Annual Healthcare Conference Date: Tuesday, November 28 – Thursday, November 30, 2023Location: The Lotte New York Palace, New York, NY Links to the presentations and webcast will be